Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bridgebio Pharma Inc (NQ: BBIO )

24.95 -0.52 (-2.02%)
Streaming Delayed Price Updated: 3:48 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,172,929
Open 25.37
Bid (Size) 24.93 (7)
Ask (Size) 24.96 (2)
Prev. Close 25.46
Today's Range 24.44 - 25.78
52wk Range 12.75 - 44.32
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Performance

YTD
-38.33%
-38.33%
1 Month
-15.12%
-15.12%
3 Month
-32.82%
-32.82%
6 Month
-0.50%
-0.50%
1 Year
+64.00%
+64.00%

More News

Read More
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Recap: BridgeBio Pharma Q4 Earnings
Via Benzinga
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 1/9
Via Investor Brand Network
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
What's Going On With BridgeBio Pharma Stock On Monday?
Via Benzinga
Exposures Product Safety
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
Via Investor's Business Daily
2 Biotechs That Could Get Bought Out in 2024
Via The Motley Fool
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
Via InvestorPlace
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
Via InvestorPlace
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.